The new volume of Advances in Diabetes Novel Insights comes at an unusual time: diabetes has reached a point where “established” concepts need a relook, changes occurred in the management of known complications; in addition, exciting avenues opened up in our understanding of diabetes, its predisposing conditions and comorbidities. Besides, artificial intelligence has made inroads into mainstream management of diabetes. COVID-19 epidemic shot both teleconsultation and corticosteroid use into the limelight.